Akebia Therapeutics, Inc.
AKBA
$1.44
$0.021.41%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -5.35M | -15.91M | -36.48M | -45.31M | -69.41M |
| Total Depreciation and Amortization | 1.27M | 10.29M | 19.35M | 28.44M | 37.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 55.60M | 46.64M | 50.24M | 36.31M | 30.92M |
| Change in Net Operating Assets | 16.47M | -8.63M | -35.51M | -54.26M | -39.68M |
| Cash from Operations | 67.99M | 32.40M | -2.40M | -34.81M | -40.66M |
| Capital Expenditure | -291.00K | -223.00K | -148.00K | -51.00K | -33.00K |
| Sale of Property, Plant, and Equipment | 172.00K | 172.00K | 172.00K | 172.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -7.81M | -- | -- | -- | -- |
| Cash from Investing | -7.93M | -51.00K | 24.00K | 121.00K | -33.00K |
| Total Debt Issued | 10.00M | 10.00M | 10.00M | 18.00M | 45.00M |
| Total Debt Repaid | -4.23M | -461.00K | -461.00K | -835.00K | -37.10M |
| Issuance of Common Stock | 68.36M | 90.62M | 91.26M | 89.55M | 43.03M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -1.21M | -63.00K | -585.00K | -585.00K | -1.27M |
| Cash from Financing | 72.93M | 100.10M | 100.21M | 106.13M | 49.66M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 132.99M | 132.45M | 97.83M | 71.44M | 8.97M |